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Significance Statement 
Vascular calcification is common in patients with CKD and is an independent contributor to increased 
vascular stiffness and vascular risk in this patient group. Vitamin K is a cofactor for proteins that inhibit 
vascular calcification. In this parallel-group, double-blind randomised controlled trial, 12 months of 
vitamin K2 supplementation did not improve vascular stiffness measured by pulse wave velocity, 
despite improvements in desphospho-uncarboxylated matrix Gla protein (an inhibitor of vascular 
calcification). An updated meta-analysis including these new results confirms a lack of efficacy of 
vitamin K supplementation on these endpoints. Longer treatment periods, or therapies other than 
vitamin K, may be required to improve vascular calcification and hence reduce arterial  stiffness and 
cardiovascular risk in patients with CKD.  
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Abstract 
Background 
Vitamin K is a cofactor for proteins involved in prevention of vascular calcification, a risk factor for 
cardiovascular disease. We tested whether vitamin K supplementation could improve arterial stiffness 
in patients with chronic kidney disease. 
 
Methods 
Parallel group, double-blind, randomised, placebo-controlled trial. Participants aged 18 and over with 
chronic kidney disease stage 3b or 4 (estimated GFR 15-45 ml/min/1.73m2) were randomised to 
receive 400mcg oral vitamin K2 or matching placebo once daily for a year. The primary outcome was 
the adjusted between-group difference in carotid-femoral pulse wave velocity at 12 months. 
Secondary outcomes included augmentation index, abdominal aortic calcification, blood pressure, 
physical function and blood markers of mineral metabolism and vascular health. We included results 
in an updated meta-analysis of trials. 
 
Results 
159 randomised participants were included in the modified intention to treat analysis; 80 were 
allocated to vitamin K and 79 to placebo. Mean age was 66 (SD 12) years, 62 (39%) were female and 
87 (55%) had CKD stage 4. No difference was seen in pulse wave velocity at 12 months (adjusted 
treatment effect -0.1m/s, 95%CI -0.9 to 0.7, p=0.77). No difference was seen in augmentation index 
at 12 months (adjusted treatment effect 0%, 95%CI -2 to 2, p=0.97), blood pressure, B-type natriuretic 
peptide or physical function. Updated meta-analysis showed no effect of vitamin K supplementation 
on vascular stiffness or measures of vascular calcification. 
 
Conclusion 
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Vitamin K2 supplementation did not improve vascular stiffness or other measures of vascular health 
in this trial. 
 
 
Trial Registration: ISRCTN21444964 
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Introduction 
Cardiovascular disease is the major cause of morbidity and mortality in patients with chronic kidney 
disease (CKD).1 Cardiovascular risk increases with worsening renal function, but risk is substantially 
increased even in those with moderate CKD; patients with stage 3b CKD have over twice the mortality 
rate of those without CKD.2 This risk persists despite efforts to control conventional cardiovascular risk 
factors including blood pressure and lipids.3 
 
Vascular calcification is common in patients with CKD, and the degree of calcification correlates with 
the severity of renal impairment.4 Calcification of elastic arteries is associated with increased vascular 
stiffness,5 an important risk factor for cardiovascular events6, driven by a series of adverse 
consequences including increased blood pressure, decreased coronary artery perfusion, and the 
development of left ventricular hypertrophy. The potential importance of vascular calcification is 
reinforced by analyses showing that it is an independent risk factor for cardiovascular events; 
abdominal aortic calcification is associated with an odds ratio of 1.6 for vascular events after 
adjustment for conventional risk factors.7 
 
It is now clear that vascular calcification is not a passive process, but is an active, regulated process 
akin to ectopic new bone formation.8 Vitamin K-dependent proteins are integral to the regulation of 
this phenomenon. Two important proteins that regulate and prevent vascular calcification – matrix 
Gla protein (MGP) and Gla-rich protein – require vitamin K as a cofactor for gamma-carboxylation: an 
essential step in their activation.9,10 Other proteins requiring vitamin K for activation, such as 
osteocalcin and Gas611,12 are also involved in bone and mineral metabolism. Vitamin K intake is low 
for a large proportion of people13 and for patients with CKD, impaired vitamin K recycling potentially 
compounds this relative deficiency of vitamin K.14 
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A recent meta-analysis of observational studies confirmed that higher levels of inactive vitamin K-
dependent proteins are associated with higher rates of cardiovascular events and death.15 Few trials 
of vitamin K have examined the impact of treatment on vascular calcification or stiffness to date, 
however meta-analyses of those that have suggest a potential significant benefit on vascular 
calcification, and a non-significant reduction in vascular stiffness.15 Only one trial to date has examined 
whether vitamin K supplementation can improve vascular calcification in patients with non-dialysis 
dependent CKD.16 This trial did not find a significant difference in coronary artery calcification between 
the vitamin K and placebo groups, but the trial was small (n=42), and the dose of vitamin K2 was low 
(90mcg per day); vascular stiffness was not tested as an outcome. The aims of the current trial were 
therefore to provide a robust test of whether 1 year of vitamin K2 supplementation (400mcg per day) 
improved pulse wave velocity and other markers of cardiometabolic health and mineral metabolism 
compared to placebo in patients with CKD stages 3b and 4.  
 
Methods 
Trial design 
We conducted a parallel-group, placebo-controlled, double-blind, randomised trial. Ethics approval 
was obtained from the East of Scotland NHS Research Ethics committee (approval number 
13/ES/0085). The trial was registered at www.isrctn.com (ISRCTN21444964). Written informed 
consent was obtained from all participants at the screening visit, and the trial was conducted 
according to the principles of the Declaration of Helsinki. The trial Sponsors were the University of 
Dundee and NHS Tayside. Tayside Clinical Trials Unit provided trial management, and the Robertson 
Centre for Biostatistics (Glasgow) provided data management and statistical analyses. 
 
Trial population and recruitment 
Participants were eligible if aged 18 years or over, with CKD stage 3b or 4 (defined as an estimated 
glomerular filtration rate [eGFR] of >15 ml/min and <45 ml/min by CKD-EPI equation17). Potential 
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participants were excluded if they were unable to give written informed consent, were taking warfarin 
or had atrial fibrillation, were taking vitamin K or had a known contraindication to vitamin K therapy, 
were pregnant, intolerant to soya products, were currently enrolled in another trial, or were within 
30 days of completing another trial. Participants were recruited via the electronic renal patient records 
at two large nephrology centres in Scotland and additionally using the NHS Research Scotland SHARE 
registry (www.registerforshare.org) 
 
Intervention and comparator 
Matching tablets containing either 400mcg of vitamin K2 (MK7 subtype), or placebo, were 
manufactured and bottled by Legosan AB (Kumla, Sweden), and distributed to sites by Tayside 
Pharmaceuticals (Dundee, Scotland). The trial product was provided in identical bottles with a unique 
trial identifier on each bottle to ensure masking to participants, clinicians and researchers. Participants 
were asked to take one tablet each day for the 12 months of the trial. No clear evidence exists to 
favour vitamin K1 or K2, or to favour a particular subtype of vitamin K2.15 However, we used the MK7 
subtype of vitamin K2 in a previous trial that suggested possible benefit on vascular stiffness18 and so 
this subtype was selected for use in the current trial, but at a higher dose than used previously. The 
dose was selected based on previous work suggesting that vitamin K2 supplementation has dose-
dependent effects on undercarboxylation of MGP in patients with CKD at least up to a level of 360mcg 
per day.19 Adherence was checked by counting returned tablets at each visit, with percentage 
adherence calculated as (number of tablets actually ingested / number of tablets expected to be 
ingested) x 100. 
 
Randomisation and allocation concealment 
Randomisation was performed in a 1:1 ratio by a web-based randomisation system, run by the 
Robertson Centre for Biostatistics, University of Glasgow, to ensure allocation concealment. A 
minimisation algorithm with a small random element was used to ensure balance across key baseline 
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measures. Minimisation factors were: study centre (Tayside or Glasgow), age (>70 years or <=70 
years), sex, CKD stage (3b or 4), and baseline pulse wave velocity (>9.5m/s or <=9.5m/s). During the 
course of the trial, a problem with the medication supply for one individual arose which called into 
question whether the contents of bottles allocated to other participants were correct. All participants 
who were taking study medication at the time had samples of their medication tested to confirm that 
the medication they were allocated matched the bottle content list held by the manufacturer. All 
tested participants except for the index individual were taking study tablets with the correct content. 
The index individual was removed from the trial and from analysis. For a further 28 individuals who 
had completed their first six month supply of medication, testing could not be carried out as no tablets 
remained to test; these individuals were removed from the trial and from analysis as it was not 
possible to know what treatment they had taken. All medication testing and comparison with 
manufacturing lists was conducted by teams separate from the investigators, research nurses, 
statisticians and clinical teams to preserve masking of participants, clinicians and the study team.   
 
The primary outcome was the between-group difference in pulse wave velocity at 12 months, adjusted 
for baseline values. We measured pulse wave velocity using the Sphygmocor system (AtCor Medical, 
Sydney, Australia) using measurements of the pulse wave at the carotid and femoral sites.20 We chose 
to measure pulse wave velocity rather than directly measuring calcification for several reasons. Any 
significant change in calcification would be expected to cause a change in arterial stiffness,5 but pulse 
wave velocity, as a marker of arterial stiffness, provides not just structural but functional information 
on large arteries. It is an independent risk factor for future cardiovascular events6,21 and requires fewer 
participants to demonstrate clinically important treatment effects than measures of vascular 
calcification.22 
 
Secondary Outcomes  
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We measured a series of other markers of vascular health. Augmentation index was derived from 
applanation tonometry at the radial artery using the Sphygmocor system (AtCor Medical, Naperville, 
Sydney, Australia). We calculated augmentation index expressed as ratio of pressure increase to pulse 
pressure normalised for a heart rate of 75 beats per minute (AIx@75) using the internal Sphygmocor 
algorithm. Office blood pressure was measured three times in the recumbent position using an 
OMROM HEP-705 oscillometric device and was recorded as the average of the second and third 
readings. 24 hour blood pressure was recorded using the SpaceLabs system (SpaceLabs Healthcare, 
Snoqualmie, WA, USA), taking half-hourly readings during daytime and hourly reading at night-time. 
Mean values derived from the whole 24 hour record are reported. 
 
Renal function was assessed using serum creatinine concentration measured as part of routine NHS 
clinical care, with estimated glomerular filtration rate derived using the CKD-EPI equation.18 Urinary 
protein/creatinine ratio was measured from a spot urine sample at baseline and 12 months. 
Osteocalcin, Tartrate resistant acid phosphatase 5b, parathyroid hormone, fetuin, Fibroblast growth 
factor-23, 25-hydroxyvitamin D, and 1,25hydroxyvitamin D were measured as markers of bone and 
mineral metabolism, and N-terminal pro B-type natriuretic peptide (NT-pro-BNP) was measured as a 
marker of vascular risk. Insulin and glucose were measured and used to calculate insulin resistance 
using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).23 Desphospho-
uncarboxylated matrix Gla protein (dp-ucMGP) was measured as a biological marker of vitamin K 
repletion; this marker has previously been shown to correlate with vascular events and is related to 
the degree of vascular calcification.15 Details of assay manufacturers and coefficients of variation for 
each blood and urine assay are given in Supplementary Material. 
  
We performed lateral abdominal radiography to assess aortic calcification. The degree of calcification 
was assessed by two independent blinded observers, scoring the degree of calcification on a scale 
from 0 to 3 for the segments of the abdominal aorta adjacent to each of lumbar vertebrae L1 to L4; 
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this method has previously been shown to correlate with risk factors for uraemic calcification.24 
Anterior and posterior walls were summed separately, giving a total score from 0 to 24 points. Vitamin 
K-dependent proteins have also been implicated in maintenance of neuromuscular function and bone 
health, and a previous trial suggested a modest improvement in postural sway with vitamin K 
supplementation.18 CKD is associated with worse physical performance and with high falls and fracture 
rates;25,26 we therefore assessed markers of muscle function as part of the trial. The Short Physical 
Performance Battery (SPPB; a test of lower limb balance, strength and function that is a powerful 
predictor of future disability, falls, need for care and death) was performed,27 along with maximal 
handgrip strength measured using a Jamar dynamometer.28 Monthly self-completed falls diaries were 
issued to participants to prospectively record falls.29 All new symptoms or unscheduled healthcare 
contacts for new problems were recorded as adverse events and coded using Medical Dictionary for 
Regulatory Activities (MedDRA) version 16.1. All measurements were conducted by trained research 
nurses masked to treatment allocation. All outcomes were measured at baseline, six and 12 months 
with the exception of vascular calcification, which was measured at baseline and 12 months. 
 
Sample size calculation 
We based our sample size calculation on detecting a 1.0 m/s improvement in pulse wave velocity in 
the intervention group relative to placebo at 12 months. This degree of improvement corresponds to 
a reduction in cardiovascular risk of between 6 and 12%.6,21 Our previous data indicated a standard 
deviation of 2.1m/s for pulse wave velocity,18 which is consistent with previously published values for 
pulse wave velocity in patients with CKD.30-32 To achieve a power of 80% with alpha=0.05 given the 
above parameters requires 70 patients per group (140 in total). We assumed a dropout of 15% per 12 
months, thus the initial target for recruitment was to randomise 166 participants. The sample size was 
recalculated during the trial to account for individuals withdrawn from the trial as a result of the 
medication issue discussed above. To ensure adequate power despite these withdrawals, a revised 
target of 190 randomised participants was set in January 2017. 
12 
 
 
Statistical analysis 
All analyses were conducted according to a prespecified Statistical Analysis Plan. Analyses were 
conducted using the statistical package SAS (version 9.3). A two-sided p value of <0.05 was taken as 
significant for all analyses in line with the sample size calculation above. Descriptive statistics were 
generated for baseline characteristics and for the adverse event data. For the primary outcome, 
Analysis of Covariance (ANCOVA) was used to determine the between-group difference at 12 months. 
Adjustments were made for gender (male/female), continuous age at baseline, study centre 
(Glasgow/Tayside), baseline continuous eGFR, and the baseline primary outcome continuous value. 
This analysis was repeated for the 6 month data to determine the between-group difference at 6 
months, making the same adjustments as for 12 months. To determine the average effect of the 
treatment over the duration of the study, repeated measures analyses were carried out adjusting for 
gender, age at baseline, site and baseline eGFR. For all analyses, the treatment effect estimates along 
with the 95% confidence intervals (CIs) were provided. For dp-ucMGP results, values below the 
threshold of reliable linear assay performance (900 pmol/L) were assigned a value of 900 pmol/L prior 
to log transformation and analysis.  
 
For each of the secondary outcomes, the ANCOVA analyses conducted for the primary outcome were 
repeated to determine the between-group difference in each of the outcomes at 12 months and 6 
months. Repeated measures analyses for the outcomes were also carried out to determine the 
average treatment effect over the duration of the study, adjusting for gender, age, study centre, 
baseline eGFR and the baseline value of the outcome being tested.  As a number of the secondary 
outcomes were biomarkers, the residual distribution of each outcome was assessed and the outcome 
data were transformed where necessary before carrying out the analyses. The falls diary data was 
assessed by comparing the incidence rate of falls between the study arms using a Poisson regression 
model. A sensitivity analysis using a negative binomial regression model was also performed.  The time 
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to first fall was then examined using a Cox Proportional Hazards model, adjusting for age, gender, 
study centre and baseline eGFR. Multiple imputation was conducted as a sensitivity analysis to 
determine the impact of missing data on the primary and secondary outcome analysis results. Ten 
imputed datasets were created, using the Markov Chain Monte Carlo method assuming multivariate 
normality, based on baseline pulse wave velocity, baseline eGFR, gender, and age at baseline. 
Thereafter the ten datasets were analysed separately using ANCOVA to determine the between-group 
differences at 12 months and the results were combined using SAS PROC MIANALYZE. 
 
Updated meta-analysis 
To assimilate our trial findings with other published trials examining the effect of vitamin K 
supplementation on vascular stiffness and calcification, we updated our recently published meta-
analysis.15 In line with this previous analysis, the percentage change in vascular stiffness score and 
vascular calcification score for each group was used and combined with scores from other trials using 
random effects models in R statistical software (R Studio version 1.0.136), with a sensitivity analysis 
performed using a fixed effects model. Revised searches were run until end December 2019, using the 
same search strategy as in our previously published analysis. 
 
Results 
A total of 189 participants were randomised between 19th January 2016 and 20th September 2017. 
Of these, 30 were withdrawn from further participation and from the analysis due to the medication 
issue described above. The analysis population therefore comprised 159 participants; 80 who received 
vitamin K and 79 who received placebo. Baseline details are given in Table 1 and participant flow 
through the trial is shown in Figure 1. The mean adherence to therapy was 91.3% (SD 11.5) in the 
vitamin K arm and 90.7% (SD 14.7) in the placebo arm. Mean log-transformed dp-ucMGP results fell 
between baseline and 12 months with vitamin K treatment (7.08 vs 6.89) but not in the placebo group 
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(7.01 vs 7.06; treatment effect -0.20 [95%CI -0.28 to -0.13]; p<0.001). Individual changes in dp-ucMGP 
are shown in Figure 2.  
 
Table 2 shows the results of the primary outcome analyses. No significant treatment effect was 
evident at 12 months (the prespecified primary outcome timepoint), at six months, or by repeated 
measures. Multiple imputation of missing data at 12 months showed no significant treatment effect 
and therefore did not change the results of the analysis. There was no significant association between 
change in log-transformed dp-ucMGP between baseline and 12 months and change in pulse wave 
velocity between baseline and 12 months (Spearmans rho = 0.08 [95% CI -0.11 to 0.26], p=0.42). 
 
Secondary vascular and physical performance outcomes are shown in Table 3. No effect of treatment 
was seen on office blood pressure, NT-pro-BNP or augmentation index. No significant treatment effect 
was seen for the SPPB or for grip strength. The number of participants with at least one fall in each 
treatment arm was similar; the rate of falls per unit time (the falls rate) was higher in the placebo 
group, but this was driven by two individuals with very frequent falls. The time to first fall was similar 
between the two groups: HR 0.79 (95% CI 0.37 to 1.69, p=0.54). A sensitivity analysis removing the 
two individuals with very high falls rates (74 and 30 falls in 12 months) showed an incident rate ratio 
for falls of 0.76 (95% CI 0.41 to 1.40, p=0.38); a further sensitivity analysis using a negative binomial 
regression model yielded an incident rate ratio of 0.80 (95% CI 0.34 to 1.87, p=0.60) 
 
Table 4 shows the results of the other secondary outcomes. Osteocalcin levels were significantly lower 
in the vitamin K group at 12 months compared to placebo, as was insulin resistance. No other 
significant treatment effects for markers of renal function or bone and mineral metabolism were 
observed. Table 5 shows adverse events in each group. No difference was seen between vitamin K 
and placebo in overall numbers of adverse events. Only small numbers of participants died or 
commenced renal replacement therapy. 
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Finally, we combined the results from the current study with results for vascular stiffness and for 
vascular calcification in an update to our recent meta-analysis. Details of the ten (nine plus the current 
trial) included studies16,18,33-39, are given in the Supplementary Material, and the results are shown in 
Figure 3 (vascular stiffness) and Supplementary Material (vascular calcification). Overall, vitamin K 
produced no significant reduction in vascular stiffness compared to placebo using a random-effects 
model: -3.1% [95%CI -6.5 to 0.3]; p=0.07), although a fixed-effects sensitivity analysis showed a 
marginally significant result (-3.2% [95%CI -5.7 to -0.7]; p=0.014). Meta-analysis of vascular 
calcification results (Supplementary Material) showed no reduction in vascular calcification score 
compared to placebo [-3.3% (95%CI -10.4 to 3.7]; p=0.37). 
 
 
Discussion 
There are extensive pre-clinical data suggesting that vitamin K-dependent proteins regulate vascular 
calcification and biological plausibility that vitamin K supplementation may prevent vascular 
calcification in patients with advanced CKD. As vascular calcification is integrally associated with 
arteriosclerosis characterised by increased pulse wave velocity, we assessed whether vitamin K 
supplementation reduced or attenuated pulse wave velocity over the course of 12 months in patients 
with stage 3b or 4 CKD. In summary, in this double-blind placebo controlled RCT, vitamin K2 had no 
effect on reducing pulse wave velocity compared to placebo. Furthermore, vitamin K2 therapy did not 
lead to any improvement in progression of vascular calcification as measured by aortic calcification on 
lateral abdominal X-ray compared to placebo. This is despite good adherence to therapy and evidence 
of lowering of dp-ucMGP levels – a key marker of vitamin K insufficiency that is associated with 
vascular calcification – in the vitamin K treatment group. An updated meta-analysis confirmed no 
significant improvement in either vascular stiffness or vascular calcification with vitamin K 
supplementation when results from the current trial were combined with previous trial results. 
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There are a number of possible reasons why vitamin K2 supplementation did not improve pulse wave 
velocity in this trial. It is possible that as arteriosclerosis is challenging to reverse, pulse wave velocity 
may not be easily amenable to intervention in advanced CKD. This is possible, but other trials have 
demonstrated that this surrogate parameter is amenable to modification in similar populations, for 
instance with vitamin D supplementation.40,41 Pulse wave velocity is generally considered a reliable 
surrogate marker for arteriosclerosis. However, it is not a direct measure of vascular calcification. 
Although calcification on abdominal X ray (AXR) is less widely used as a marker of vascular calcification 
than coronary calcification, AXR calcification has been clearly associated with future cardiovascular 
events in the Framingham studies.42 It is possible that treatment for longer than 12 months is 
necessary to produce a detectable impact on vascular calcification or on vascular stiffness, 
phenomena that often progress slowly over many years. A previous trial examining the effect of 
vitamin K supplementation in post-menopausal women found no effect on vascular stiffness until the 
third year of treatment.35 However, in the current study vitamin K2 was not associated with 
improvement in other circulating markers of mineral metabolism such as Fetuin-A concentrations, a 
biomarker implicated in the prevention of vascular calcification.43. The exception was a change in 
osteocalcin levels in the vitamin K treatment group, but as osteocalcin is itself a vitamin K-dependent 
protein, the significance of this change in terms of future vascular calcification risk is difficult to 
interpret. The change in osteocalcin does however give additional evidence that vitamin K 
supplementation was producing actions in vivo consistent with the known biological roles of vitamin 
K. 
 
A second possibility is that participants in our trial were vitamin K replete. Although the circulating dp-
ucMGP levels in our trial population were lower than those seen in some other populations (e.g. those 
on haemodialysis38), the fact that dp-ucMGP levels fell further in the vitamin K supplementation group 
suggests that this group of patients were not replete in vitamin K, although they may still have had 
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levels of active MGP sufficient to inhibit vascular calcification to some extent. We did not attempt to 
select trial participants on the basis of their vitamin K repletion status; to do so would have required 
screening participants using the dp-ucMGP assay which is not widely available as a clinical test. It is 
possible that any treatment effect could have been diluted by recruiting a mixed population of replete 
and non-replete participants. Future studies could measure dietary vitamin K intake to select 
participants with particularly low vitamin K intakes. A third possibility is that the dose of vitamin K2 
used in our trial was not sufficient to alter vascular calcification or vascular stiffness. We cannot 
discount this possibility, but we note that higher doses of vitamin K2 (equivalent to 860mcg per day) 
used in the recent multicentre VALKYRIE trial38 also failed to improve measures of vascular 
calcification.      
 
Other trials have tested vitamin K2 supplementation in patients with CKD, although the focus for most 
other trials has been patients undergoing haemodialysis. Recent open label clinical trials for patients 
undergoing haemodialysis have also not shown any benefit of vitamin K2 supplementation on aortic 
calcification in haemodialysis patients37 and no benefit on coronary calcification in combination with 
rivaroxaban in haemodialysis patients previously treated with vitamin K antagonist anticoagulants.38 
One short (8 weeks) single arm non-randomised clinical study of vitamin K2 supplementation 
demonstrated improvement in PWV in renal transplant recipients.44 Therefore, our results in 
advanced non-dialysis dependent CKD are in keeping with other similar trials in patients undergoing 
dialysis. 
 
Few studies have examined the effect of vitamin K supplementation on measures of physical 
performance in any population. One small trial suggested a possible benefit on postural sway in older 
people with vascular disease18 but a more recent trial, testing a similar dose of vitamin K2 to that used 
in the current trial over 1 year in older people with a history of falls, found no effect on postural sway, 
falls, or measures of physical performance.45 Our findings are therefore in keeping with this more 
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recent trial. Controversy continues as to whether vitamin K supplementation has a significant impact 
on bone mineral density or fracture in people with osteoporosis; previous reviews have been clouded 
by the inclusion of fraudulent trial results. The most recent meta-analysis suggests no significant effect 
on bone mineral density from vitamin K supplementation but is unable to confirm or exclude a 
clinically important effect on fracture risk.46 
 
Strengths of our trial include adequate power to detect a relatively small change in pulse wave 
velocity, the use of more than one centre to recruit participants, and the use of a placebo control to 
ensure masking of outcomes assessments and analyses. However, there are a number of limitations. 
Despite our trial population having a mean age of 66 years, this is still younger than most patients with 
CKD stages 3b and 4 seen in clinical practice. Similarly, more men than women took part in the trial, 
and the trial population were overwhelmingly white. Our results may not therefore be generalisable 
to older populations, centres with a non-white ethnic population, or patients with CKD stage 5. The 
duration of intervention was limited to 1 year, and it is possible that a longer intervention period 
would have produced a greater treatment effect; similarly a higher dose of vitamin K or targeting of 
those most deficient in vitamin K might have delivered greater improvements. Our method of 
measuring vascular calcification was relatively crude, and the length of our study is unlikely to have 
been long enough to demonstrate prevention of progression of calcification; our ability to detect 
reductions in calcification is limited by the fact that some participants did not have detectable 
calcification on plain abdominal radiographs. A range of different populations, interventions and 
methods of outcome measurement are included in the meta-analysis. This variation is likely to 
introduce substantial heterogeneity, and these results should be interpreted with caution. We chose 
to present results using a random-effects analysis for the main estimate, in part because of this 
expected heterogeneity, and because such analyses tend to the conservative in deriving broader 
confidence intervals than seen with fixed-effect analyses. 
 
19 
 
Based on data from our trial and other recent studies, it does not seem likely that vitamin K 
supplementation is an effective therapy to prevent or reverse vascular calcification. Alternative 
strategies to address vascular calcification have recently emerged including a recent clinical trial 
suggesting that SNF472 (intravenous myo-inositol hexaphosphate) which inhibits formation and 
growth of hydroxyapatite, attenuates progression of coronary artery calcification in haemodialysis 
patients.47 Sodium thiosulfate is often advocated as a treatment for calciphylaxis as it is proposed to 
mobilise calcium from deposits and forms soluble calcium thiosulphate complexes.48 It has been 
shown to have some benefits on vascular calcification in dialysis patients in some studies.49 Other 
strategies are likely to emerge (for instance manipulating fetuin-A activity) as our understanding of 
the biology of vascular calcification continues to advance.43 
 
In conclusion, based on our prior assumption that PWV is a meaningful surrogate for further 
cardiovascular events in patients with CKD, our results do not support the hypothesis that 
administration of vitamin K2 will reduce cardiovascular events in this population. Combining our 
results with other recent trials does not currently support the conduct of a large cardiovascular 
outcome trial using vitamin K2 therapy; instead, alternative methods to improve vascular stiffness in 
patients with CKD should be explored. 
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Table 1. Baseline characteristics of full analysis dataset 
 
 Vitamin K (n=80) Placebo (n=79) 
Mean age (years) (SD) 67.3 (11.0) 65.7 (13.5) 
Age >70 years (%) 35 (44) 37 (47) 
Age <=70 years (%) 45 (56) 42 (53) 
Female sex (%) 32 (40) 30 (38) 
White ethnicity (%) 76 (95) 77 (98) 
Cause of renal 
dysfunction (%) 
Hypertension 18 (23) 13 (17) 
Diabetes mellitus 18 (23) 16 (20) 
Glomerulonephritis 10 (13) 8 (10) 
Polycystic kidney disease 7 (9) 5 (6) 
Vascular disease 5 (6) 7 (9) 
Other 29 (36) 32 (41) 
Not known 5 (6) 5 (6) 
Cardiovascular 
comorbidity (%) 
Ischaemic heart disease* 10 (13) 15 (19) 
Stroke 7 (9) 7 (9) 
Heart failure 1 (1) 4 (5) 
Peripheral vascular disease 6 (8) 4 (5) 
 Hypertension 69 (86) 63 (80) 
 Diabetes mellitus 26 (33) 27 (34) 
Previous fragility fracture (%) 5 (6) 3 (4) 
Walking aids (%) 19 (24) 12 (15) 
Current smoker (%) 6 (8) 12 (15) 
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Median number of medications (IQR) 7 (4,10) 7 (4,10) 
Medication use:  ACEi/ARB 49 (61) 50 (63) 
 Phosphate binder 1 (1) 0 (0) 
 Erythropoietin 4 (5) 5 (6) 
 Iron 12 (15) 7 (9) 
Mean eGFR (ml/min/1.73m2) (SD) 29 (8) 30 (8) 
Chronic kidney disease stage 3b vs 4 (%) 37 vs 43  
(46% vs 54%) 
35 vs 44  
(44% vs 56%) 
Mean pulse wave velocity (m/s) (SD) 11.9 (3.5) 11.4 (3.2) 
Mean augmentation index (%)(SD) 26 (11) 25 (10) 
Mean office blood pressure (mmHg) (SD) 147/78 (27/12) 137/74 (19/10) 
Mean postural blood pressure drop (mmHg) (SD) 15/4 (18/8) 9/3 (18/9) 
Mean 24 hour blood pressure (mmHg) (SD) 128/69 (16/11) 130/70 (17/10) 
Mean Short physical performance battery score (SD) 9.1 (2.6) 9.4 (2.6) 
Mean handgrip 
strength (kg) (SD) 
Males 31.7 (12.1) 30.2 (9.8) 
Females 14.5 (6.1) 16.6 (6.1) 
Median NT-pro-BNP (IQR) (pg/ml) (Q1, Q3) 1494 (415,4133) 2274 (585, 5801) 
Median Fetuin (IQR) (ng/ml) (Q1, Q3) 1237 (1005,1535) 1359 (1090, 1847) 
Median FGF-23 (IQR) (RU/ml) (Q1, Q3) 170 (126,255) 156 (113,218) 
Median Parathyroid hormone (IQR) (pmol/L) (Q1, Q3) 14 (8,22) 13 (8,19) 
Median TRACP-5b (IQR) (mIU/ml) (Q1, Q3) 0.41 (0.28, 0.88) 0.55 (0.30, 1.27) 
Median Osteocalcin (ng/ml) (Q1, Q3) 37 (24, 62) 36 (24, 52) 
Mean 25-hydroxyvitamin D (nmol/L) (SD) 48 (29) 44 (23) 
Mean 1,25-hydroxyvitamin D (pmol/L) (SD) 74 (33) 69 (29) 
Mean Adjusted calcium (mmol/L) (SD) 2.33 (0.11) 2.33 (0.14) 
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Mean Phosphate (mmol/L) (SD) 1.17 (0.19) 1.18 (0.20) 
Median HOMA IR (Q1, Q3) 2.36 (1.46, 3.66) 2.02 (1.44, 3.78) 
Median urinary protein/creatinine ratio (mg/mmol) 
(Q1, Q3) 
36 (5,141) 40 (5,104) 
Median aortic calcification score (Q1, Q3) 3.5 (0,9) 2 (0,6.5) 
ACEi: Angiotensin converting enzyme inhibitor. ARB: Angiotensin receptor blocker. eGFR: estimated 
Glomerular Filtration Rate. NT-pro-BNP: N-terminal pro B-type natriuretic peptide. TRACP-5b: 
Tartrate-resistant acid phosphatase 5b. FGF: Fibroblast growth factor. HOMA-IR: Homeostatic 
assessment insulin resistance 
*previous myocardial infarction, percutaneous coronary angioplasty, coronary artery bypass grafting 
or diagnosis of angina 
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Table 2. Primary outcome: Carotid-femoral Pulse Wave Velocity (m/s) 
 n Vitamin K 
Mean (SD) 
n Placebo 
Mean (SD) 
Unadjusted Treatment 
effect (95% CI) 
p Adjusted Treatment 
effect* (95% CI) 
p 
6 months 57 11.7 (3.2) 63 11.1 (3.1) 0.56 (-0.58 to 1.70) 0.33 0.12 (-0.66 to 0.90) 0.76 
12 months 55 11.7 (3.2) 59 11.7 (3.6) -0.03 (-1.31 to 1.25) 0.96 -0.12 (-0.93 to 0.69) 0.77 
Repeated measures - - - - - - 0.01 (-0.66 to 0.68) 0.98 
Multiple imputation: 
12 months 
- - - - - - -0.11 (-0.89 to 0.68) 0.79 
Sensitivity analysis** 
(6 months) 
70 11.6 (3.3) 78 11.1 (3.1) 0.52 (-0.53 to 1.57) 0.33 0.20 (-0.51 to 0.90) 0.59 
*Adjusted for age, sex, eGFR, site and baseline values 
** includes participants removed from main analysis due to uncertainty about medication content 
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Table 3. Secondary outcomes – vascular and physical function 
  Vitamin K 
Mean (SD) 
Placebo 
Mean (SD) 
Treatment effect* 
(95% CI) 
p 
Office systolic 
blood pressure 
(mmHg) 
6 months 139 (22) 134 (18) 0 (-5 to 5) 0.96 
12 months 139 (23) 137 (21) -2 (-8 to 4) 0.58 
Repeated 
measures 
  0 (-5 to 4) 0.86 
Office diastolic 
blood pressure 
(mmHg) 
6 months 76 (11) 74 (10) 1 (-2 to 3) 0.65 
12 months 75 (10) 74 (10) -1 (-4 to 1) 0.32 
Repeated 
measures 
  0 (-3 to 2) 0.70 
Augmentation 
index (%) 
6 months 24 (10) 23 (11) 0 (-2 to 2) 0.72 
12 months 25 (10) 25 (9) 0 (-2 to 2) 0.97 
Repeated 
measures 
  0 (-2 to 2) 0.94 
Log [NT-pro-
BNP (pg/ml)] 
12 months 7.46 (1.29) 7.47 (1.53) 0.10 (-0.20 to 0.39) 0.51 
SPPB 6 months 9.3 (2.8) 9.6 (2.2) 0.1 (-0.5 to 0.7) 0.71 
12 months 9.1 (3.0) 9.8 (2.2) -0.4 (-1.0 to 0.3) 0.29 
Repeated 
measures 
  -0.1 (-0.6 to 0.4) 0.74 
Grip strength 
(kg) 
6 months 24.0 (11.6) 25.5 (10.7) -0.2 (-1.7 to 1.2) 0.75 
12 months 24.1 (11.9) 23.8 (10.6) -0.2 (-2.1 to 1.8) 0.88 
Repeated 
measures 
  -0.4 (-1.9 to 1.1) 0.59 
Number with at least one fall 13 15   
Falls / months of fall diary 
data (falls rate per month) 
18/759  
(0.024) 
128/795 
(0.161) 
0.147**  
(0.090 to 0.241) 
<0.001 
SPPB: Short Physical Performance Battery. NT-pro-BNP: N terminal pro B-type natriuretic peptide 
*Adjusted for age, sex, eGFR, site and baseline values 
**incident rate ratio 
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Table 4. Secondary outcomes – blood and urine measures at 12 months 
 Vitamin K 
Mean (SD) 
Placebo 
Mean (SD) 
Treatment effect* 
(95% CI) 
p 
eGFR (ml/min/1.73m2) 29 (9) 29 (10) 0 (-2 to 2) 0.96 
Log [HOMA-IR] 0.68 (0.79) 0.90 (1.01) -0.32 (-0.57 to -0.08) 0.01 
Log [Osteocalcin (ng/ml)] 2.70 (0.77) 3.62 (0.69) -0.93 (-1.14 to -0.73) <0.001 
Log [TRACP-5b (mIU/mL)] -0.88 (1.10) -0.76 (1.38) -0.18 (-0.53 to 0.18) 0.32 
Log [PTH (pmol/L)] 2.46 (0.76) 2.48 (0.69) -0.05 (-0.20 to 0.10) 0.50 
Phosphate (mmol/L) 1.19 (0.19) 1.19 (0.21) 0.01 (-0.05 to 0.07) 0.83 
Calcium (mmol/L) 2.33 (0.11) 2.32 (0.12) 0.01 (-0.02 to 0.04) 0.61 
Log [Fetuin (ng/ml)] 7.14 (0.33) 7.22 (0.31) 0.01 (-0.07 to 0.09) 0.81 
Log [FGF-23 (RU/ml)] 5.33 (0.71) 5.34 (0.83) -0.10 (-0.28 to 0.07) 0.23 
Log [25OHD (nmol/L)] 3.84 (0.63) 3.75 (0.54) 0.04 (-0.09 to 0.17) 0.57 
Log [1,25OHD (pmol/L)] 4.18 (0.51) 4.14 (0.38) 0.06 (-0.08 to 0.19) 0.39 
Log [Urine P/Cr ratio (mg/mmol)] 3.85 (1.12) 3.76 (1.54) -0.02 (-0.49 to 0.46) 0.95 
 
*Adjusted for age, sex, eGFR, site and baseline values 
eGFR: estimated Glomerular Filtration Rate. HOMA-IR: Homeostatic Model Assessment – insulin 
resistance. TRACP: Tartrate-resistant acid phosphatase. PTH: Parathyroid hormone. FGF: Fibroblast 
growth factor. 25OHD: 25-hydroxyvitamin D. 1,25OHD: 1,25-dihydroxyvitamin D. P/Cr: 
Protein/Creatinine 
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Table 5. Number of participants* with adverse events by MedDRA System Order Class (SOC), 
number of deaths and participants who commenced renal replacement therapy. 
 Vitamin K (n=95) Placebo (n=94) 
Any event (%) 69 (72) 68 (72) 
   
Blood and lymphatic (%) 3 (3) 4 (4) 
Cardiac (%) 5(5) 4 (4) 
Congenital and genetic (%) 1 (1) 0 (0) 
Ear and labyrinth (%) 0 (0) 1 (1) 
Endocrine (%) 0 (0) 1 (1) 
Eye (%) 0 (0) 1 (1) 
Gastrointestinal (%) 13 (14) 12 (13) 
General (%) 2 (2) 1 (1) 
Hepatobiliary (%) 1 (1) 3 (3) 
Immune system (%) 0 (0) 1 (1) 
Infections and infestations (%) 29 (31) 30 (32) 
Injury, poisoning and procedural complications (%) 19 (20) 14 (15) 
Investigations (%) 3 (3) 9 (10) 
Metabolism and nutrition (%) 9 (9) 4 (4) 
Musculoskeletal (%) 8 (8) 13 (14) 
Neoplasms (%) 2 (2) 1 (1) 
Nervous system (%) 5 (5) 10 (11) 
Psychiatric (%) 0 (0) 2 (2) 
Renal and urinary (%) 9 (9) 6 (6) 
Reproductive and breast (%) 0 (0) 1 (1) 
Respiratory (%) 4 (4) 6 (6) 
Skin (%) 11 (12) 4 (4) 
Surgical/medical procedures (%) 11 (12) 9 (10) 
Vascular (%) 3 (3) 3 (3) 
   
Deaths (%) 2 (3) 1 (1) 
Commenced renal replacement therapy** (%) 1 (1) 1 (1) 
*All 189 randomised individuals included in adverse event analysis 
**Haemodialysis, peritoneal dialysis or renal transplant 
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Figure 1. CONSORT flow diagram 
FAS: Full analysis set 
 
Figure 2. Individual change in dp-ucMGP levels between baseline and 12 month follow-up 
Dp-ucMGP: Desphospho-uncarboxylated matrix Gla protein 
 
Figure 3. Forest plot – vascular stiffness 
a. Without current trial 
b. With current trial 
 
 
 
